T-reg transcriptomic signatures identify response to check-point inhibitors.

When we used these genes as a signature using a mean of expression of all genes (10 genes), we observed an association with favourable outcome, being statistically borderline significant for PD1 treatment, and the association was strongly positive for anti-CTLA4 or combinatorial therapies (Anti PD1: HR = 0.75; CI 0.56–1.01; p = 0.06; Anti CTLA4: HR = 0.42; CI 0.24–0.74; p = 0.002; Anti PD1 + Anti CTLA4: HR = 0.21; CI 0.07–0.61; p = 0.0018) (Fig. 7 b).

also in 11,409 other papers